By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Biotechnology have been published. According to news reporting originating in Boston, Massachusetts, by NewsRx journalists, research stated, "Lentiviral vectors are promising tools for the genetic modification of cells in biomedical research and gene therapy. Their use in recent clinical trials for the treatment of adrenoleukodystrophy, beta-thalassemia, Wiskott-Aldrich-Syndrome and metachromatic leukodystrophy underlined their efficacy for therapies especially in case of hereditary diseases."
The news reporters obtained a quote from the research from Harvard University, "In comparison to gammaretroviral LTR-driven vectors, which were employed in the first clinical trials, lentiviral vectors present with some favorable features like the ability to transduce also non-dividing cells and a potentially safer insertion profile. However, genetic modification with viral vectors in general and stable integration of the therapeutic gene into the host cell genome bear concerns with respect to different levels of personal or environmental safety. Among them, insertional mutagenesis by enhancer mediated dysregulation of neighboring genes or aberrant splicing is still the biggest concern. However, also risks like immunogenicity of vector particles, the phenotoxicity of the transgene and potential vertical or horizontal transmission by replication competent retroviruses need to be taken into account. This review will give an overview on biosafety aspects that are relevant to the use of lentiviral vectors for genetic modification and gene therapy."
According to the news reporters, the research concluded: "Furthermore, assay systems aiming at evaluating biosafety in preclinical settings and recent promising clinical trials including efforts of monitoring of patients after gene therapy will be discussed."
For more information on this research see: Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy. Current Gene Therapy, 2013;13(6):453-468. Current Gene Therapy can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Gene Therapy - www.benthamscience.com/cgt/index.htm)
Our news correspondents report that additional information may be obtained by contacting M. Rothe, Harvard University, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA, United States. Additional authors for this research include U. Modlich and A. Schambach (see also Biotechnology).
Keywords for this news article include: Biotechnology, Boston, Therapy, Massachusetts, United States, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC